Lyme Disease Vaccine Pipeline: VLA15 Phase 3, mRNA & Novel Candidates

Current Landscape

No licensed human Lyme vaccine since LYMErix withdrawal (2002). Multiple platforms in development targeting Borrelia burgdorferi outer surface proteins.

Leading Candidates

CandidatePlatformTargetStageDeveloper
VLA15Recombinant OspA (6 serotypes)OspAPhase 3 (VALOR trial, NCT05477524)Valneva/Pfizer
LYMErix-NextGenRecombinant OspA + novel adjuvantOspAPreclinical/Phase 1GSK + academic partners
OspA-conjugate vaccinesProtein-polysaccharide conjugateOspA + carrierPreclinicalMultiple (Yale, CDC, etc.)
Multivalent/chimericMulti-antigen (OspA, OspC, DbpA, BBK32)Broad strain coveragePreclinical/Phase 1Various
mRNA/saRNA vaccinesLipid nanoparticle mRNAOspA, OspC, etc.PreclinicalModerna, Pfizer/BioNTech, academic
Inactivated whole-cellKilled B. burgdorferiBroad antigen repertoirePreclinicalMultiple

Key Challenges

  • Antigenic diversity across Borrelia genospecies (US vs. Europe).
  • Safety signal from LYMErix (autoimmune arthritis concerns—HLA-DR4 linkage).
  • Correlates of protection not fully defined.
  • Endemic-area trial logistics, cost-effectiveness.

Timeline

VLA15 Phase 3 completion ~2025; potential licensure 2026–2027 if efficacy/safety confirmed. Other platforms 5–10 years away.

Lyme Disease - Related Articles